PATENT CLAIM ANALYSIS

Application Number: 15746970
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-11
Patent Classification: ["435", "173400"]

Abstract:
The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 401 or 408 is mutated.

Claim (Index 3):
The mutated factor X polypeptide of  claim 1  wherein the glutamic acid residue (E) at position 401 is substituted by an amino acid residue selected from the group consisting of glutamine (Q), alanine (A), lysine (K) and arginine (R).

Metadata:
- Claim Count in Document: 17.0
- Percentile: 86.0
- Lexical Diversity: 1.33333
- Patent Class: 435.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15542218', '13139367', '13909323', '14244840', '13732465']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.60627013174511
- 35 USC 102 Novelty (BERT): 0.5705529168599232
- Combined Prediction Score: 0.6026984102565913
- Mean Citation Score: 322.317072
- Max Citation Score: 478.6959
- Similarity Product: 397.26580252507927

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test